Measuring disease activity in COPD : is clinically important deterioration the answer?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized clinical management is key to optimizing patient outcomes. Important treatment goals include minimizing disease activity and preventing disease progression; however, quantification of these components remains a challenge. Growing evidence suggests that decline over time in forced expiratory volume in 1 s (FEV1), traditionally the key marker of disease progression, may not be sufficient to fully determine deterioration across COPD populations. In addition, there is a lack of evidence showing that currently available multidimensional COPD indexes improve clinical decision-making, treatment, or patient outcomes. The composite clinically important deterioration (CID) endpoint was developed to assess disease worsening by detecting early deteriorations in lung function (measured by FEV1), health status (assessed by the St George's Respiratory Questionnaire), and the presence of exacerbations. Post hoc and prospective analyses of clinical trial data have confirmed that the multidimensional composite CID endpoint better predicts poorer medium-term outcomes compared with any single CID component alone, and that it can demonstrate differences in treatment efficacy in short-term trials. Given the widely acknowledged need for an individualized holistic approach to COPD management, monitoring short-term CID has the potential to facilitate early identification of suboptimal treatment responses and patients at risk of increased disease progression. CID monitoring may lead to better-informed clinical management decisions and potentially improved prognosis.
| Errataetall: |
ErratumIn: Respir Res. 2021 Nov 20;22(1):299. - PMID 34801035 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Respiratory research - 21(2020), 1 vom: 02. Juni, Seite 134 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Dave [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bronchodilator Agents |
|---|
| Anmerkungen: |
Date Completed 02.04.2021 Date Revised 21.11.2021 published: Electronic ErratumIn: Respir Res. 2021 Nov 20;22(1):299. - PMID 34801035 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-020-01387-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310674530 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310674530 | ||
| 003 | DE-627 | ||
| 005 | 20231225140612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-020-01387-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310674530 | ||
| 035 | |a (NLM)32487202 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Dave |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Measuring disease activity in COPD |b is clinically important deterioration the answer? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2021 | ||
| 500 | |a Date Revised 21.11.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Respir Res. 2021 Nov 20;22(1):299. - PMID 34801035 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized clinical management is key to optimizing patient outcomes. Important treatment goals include minimizing disease activity and preventing disease progression; however, quantification of these components remains a challenge. Growing evidence suggests that decline over time in forced expiratory volume in 1 s (FEV1), traditionally the key marker of disease progression, may not be sufficient to fully determine deterioration across COPD populations. In addition, there is a lack of evidence showing that currently available multidimensional COPD indexes improve clinical decision-making, treatment, or patient outcomes. The composite clinically important deterioration (CID) endpoint was developed to assess disease worsening by detecting early deteriorations in lung function (measured by FEV1), health status (assessed by the St George's Respiratory Questionnaire), and the presence of exacerbations. Post hoc and prospective analyses of clinical trial data have confirmed that the multidimensional composite CID endpoint better predicts poorer medium-term outcomes compared with any single CID component alone, and that it can demonstrate differences in treatment efficacy in short-term trials. Given the widely acknowledged need for an individualized holistic approach to COPD management, monitoring short-term CID has the potential to facilitate early identification of suboptimal treatment responses and patients at risk of increased disease progression. CID monitoring may lead to better-informed clinical management decisions and potentially improved prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CID | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a Clinically important deterioration | |
| 650 | 4 | |a Deterioration | |
| 650 | 4 | |a Health status | |
| 650 | 4 | |a Long-term outcome | |
| 650 | 4 | |a Lung function | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 700 | 1 | |a Criner, Gerard J |e verfasserin |4 aut | |
| 700 | 1 | |a Naya, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Paul W |e verfasserin |4 aut | |
| 700 | 1 | |a Tombs, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Lipson, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Han, MeiLan K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 21(2020), 1 vom: 02. Juni, Seite 134 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:02 |g month:06 |g pages:134 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-020-01387-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 1 |b 02 |c 06 |h 134 | ||